Where were the breakthrough drugs for diabetes at ADA?

Ryan McBride None were there. The FDA has pinned "breakthrough" status this year on more than a dozen drugs, mostly for cancer and rare diseases. Diabetes therapies have been ...

Lexicon Presents Data at the American Diabetes Association Meeting

barbara.lempert Lexicon Presents Data at the American Diabetes Association Meeting On Blood Pressure Reduction and Weight Loss In Clinical Trial of LX4211 THE WOODLANDS, Texas, June ...

Glaxo’s diabetes drug fails to beat Takeda’s Actos in head-to-head study

Ryan McBride CHICAGO–GlaxoSmithKline's experimental diabetes drug proved to be at least as good at controlling blood sugar as most–but not one–in a series of late-stage ...

Who were the winners at this year’s diabetes meeting?

Tracy Staton The American Diabetes Association's annual meeting delivered its usual deluge of new data on treatments for the fast-growing disease. Our sister publication, FierceBiotech, ...

ADA roundup: Eli Lilly, Sanofi, Novo vie for center stage at diabetes confab

Ryan McBride We're put together snippets from the top ADA stories over the weekends with links to the full articles below. If you haven't done so already, please open the special ...

Industry Voices: Innovation–Not Imitation–Needed in Diabetes Drug Development

Alok Saboo Imitation may be the sincerest form of flattery, but it may also be contributing to suboptimal treatment outcomes for patients. The current pipeline of drugs to ...

Novo Nordisk’s R&D chief sizes up diabetes rivals and scandal-wary FDA

Ryan McBride Novo Nordisk has begun to regroup after the FDA denied approval of its blockbuster hopeful, Tresiba, seeking cardiovascular outcomes data on the long-acting insulin ...

Biotech startup Elcelyx scores upbeat diabetes data on reinvented metformin

Ryan McBride FierceBiotech News

GlaxoSmithKline reveals mixed results for diabetes contender in ‘crowded area’

Ryan McBride As has often been the case with GlaxoSmithKline's GLP-1 candidate albiglutide, a late-stage study in diabetics taking the drug and metformin offered some upbeat and ...

Sanofi spotlights new PhIII diabetes data for son of Lantus

Ryan McBride CHICAGO–Sanofi has provided the first glimpse at Phase III data for new insulin glargine, which is a next-generation version of its top-selling diabetes drug Lantus. FierceBiotech ...

10 Top-selling Diabetes Drugs – 2012

Eric Palmer The prevalence of diabetes is growing globally, and with that the size of the diabetes drug market. But the market has gotten increasingly competitive and increasingly complex. ...

Newly minted Sanofi diabetes med fails to impress German pricing regulators

Tracy Staton Sanofi's new diabetes drug hit a setback in Germany. The country's increasingly strict pricing regulators say Lyxumia delivers "no additional benefit" ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS